Coronavirus vaccine candidate induces immune response, trial results indicate

Scientists found that the RNA vaccine, called BNT162b1, was generally well-tolerated, although some participants experienced mild to moderate side-effects.

A coronavirus vaccine being worked on by American researchers induces a robust immune response in healthy adults, results from early phases of clinical trials suggest.

Scientists found that the RNA vaccine, called BNT162b1, was generally well-tolerated, although some participants experienced mild to moderate side-effects.